News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 29, 2024

Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection

Author(s)Ryan Haumschild, PharmD, MS, MBA, Roy Beveridge, MD, Brian T. Hill, MD, PhD

Experts discuss leveraging MAICs for decision-making when choosing a CLL BTK inhibitor.

Episodes in this series

A panel of 4 experts on CLL

EP. 1 Recent Trends and Innovations in the Management of CLL

A panel of 4 experts on CLL

EP. 2 CLL Treatment Landscape: Overview of BTK Inhibitors

A panel of 4 experts on CLL

EP. 3 Evaluating Value of BTK Inhibitors in CLL Treatment

A panel of 4 experts on CLL

EP. 4 Factors Influencing Choice of Second-Generation BTKi Monotherapy

A panel of 4 experts on CLL

EP. 5 Empowering Patients: Key Considerations for BTK Inhibitor Adherence

A panel of 4 experts on CLL

EP. 6 Optimizing Therapy Sequencing in CLL

A panel of 4 experts on CLL

EP. 7 Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection

A panel of 4 experts on CLL

EP. 8 Decision-Making in CLL: The Role of Real-World Evidence

A panel of 4 experts on CLL

EP. 9 Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment

A panel of 4 experts on CLL

EP. 10 Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization

A panel of 4 experts on CLL

EP. 11 Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers 

A panel of 4 experts on CLL

EP. 12 The Inflation Reduction Act: Implications for Patient Access in CL

A panel of 4 experts on CLL

EP. 13 Patient Access Advocacy for BTK Inhibitors

A panel of 4 experts on CLL

EP. 14 Future Directions of BTK Inhibitors in Leukemia and Lymphoma

Video content above is prompted by the following question(s):

How do you choose between BTK inhibitors in patients with relapsed/refractory (R/R) CLL?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Zanubrutinib | Image Credit: © luchschenF-stock.adobe.com

Zanubrutinib Outlasting Acalabrutinib in CLL

ByMaggie L. Shaw

August 17th 2026

Madhav Seshadri, MD

CAR T, Bispecifics Reshape Relapsed Lymphoma Care: Madhav Seshadri, MD

ByGiuliana Grossi,Madhav Seshadri, MD

August 12th 2026

Microtubes | Image Credit: © luchschenF-stock.adobe.com

Orelabrutinib Cuts Progression Risk 68% in Frontline CLL/SLL

ByMaggie L. Shaw

August 11th 2026

Kerry Rogers, MD

Science Fiction Made Real: Kerry Rogers, MD, on How CAR T Works

ByMaggie L. Shaw,Kerry Rogers, MD

August 8th 2026

Leukemiatest | Image Credit: © Богдан Стеблянко-stock.adobe.com

Infection Remains a Major Burden in Blood Cancers

ByMaggie L. Shaw

August 5th 2026